kinesin family member 3A pseudogene 1Genealiases: []
Q-omics provides the consensus-scored KIF3AP1 profile across patient tissues and cancer cell-line models. KIF3AP1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, KIF3AP1 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, KIF3AP1 RNA expression shows 6,854 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, KIRC, and STAD as cancer lineages where KIF3AP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF3AP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF3AP1 survival associations across molecular data types. KIF3AP1 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF3AP1 RNA expression–survival associations across cancer types. High KIF3AP1 expression shows unfavorable associations in UCEC, THCA, ESCA, BLCA and SARC, but favorable associations in CESC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for KIF3AP1 RNA expression.
This table summarizes KIF3AP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KIF3AP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF3AP1 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in LUAD and PAAD. The KIRC box plot shows higher KIF3AP1 RNA expression in normal versus tumor tissue (log2 FC = −0.076, t-test p < 0.001).
This table shows molecular features associated with KIF3AP1 in patient tissues and cancer cell lines. In patient samples, KIF3AP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
